<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948151</url>
  </required_header>
  <id_info>
    <org_study_id>SST-6006-013</org_study_id>
    <nct_id>NCT04948151</nct_id>
  </id_info>
  <brief_title>Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder</brief_title>
  <acronym>RESPOND</acronym>
  <official_title>A Phase 2b, Multi-Center, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sildenafil Cream, 3.6% in Premenopausal Patients With Female Sexual Arousal Disorder (FSAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Strategic Science &amp; Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daré Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Strategic Science &amp; Technologies, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking to minimize side effects, while maintaining and potentially improving&#xD;
      the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by&#xD;
      providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SFQ28 (AS) - 28 Day Recall</measure>
    <time_frame>SFQ28 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.</time_frame>
    <description>Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the Arousal-Sensation Domain of the SFQ28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSDS-DAO (Q14) - 28 Day Recall</measure>
    <time_frame>Q14 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.</time_frame>
    <description>Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the score for feeling concerned by difficulties with sexual arousal - Item #14 only of the FSDS-DAO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arousal Diary (SSE)</measure>
    <time_frame>measured by daily prompt within 24hrs after each sexual event during the Single-Blind Placebo Run-In compared to the last 4 weeks of the Double-Blind Dosing Period.</time_frame>
    <description>Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the number of Satisfactory Sexual Events, question #11 in teh ARousal Diary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Female Sexual Arousal Disorder</condition>
  <arm_group>
    <arm_group_label>Sildenafil Cream, 3.6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Patients will apply 2-gram applications up to 9 times per month.</description>
    <arm_group_label>Sildenafil Cream, 3.6%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will apply 2-gram applications up to 9 times per month</description>
    <arm_group_label>Placebo Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - For Patient Eligibility&#xD;
&#xD;
          1. Patient must be a premenopausal woman, 21 years or older.&#xD;
&#xD;
             a. Transgender individuals assigned a female gender at birth will be permitted to&#xD;
             enroll provided they are not currently undergoing hormone treatment, have not&#xD;
             undergone gender reassignment surgery and do not intend to for the duration of the&#xD;
             study.&#xD;
&#xD;
          2. Patient is fluent in the English language.&#xD;
&#xD;
          3. Patient is capable of understanding and complying with the protocol and agrees to sign&#xD;
             the informed consent document.&#xD;
&#xD;
          4. Patient has been in a stable, monogamous, relationship that was secure and&#xD;
             communicative, for at least 6 months prior to Visit 1. The relationship is with one&#xD;
             sexual partner, who is sexually functional, both psychologically and physically. The&#xD;
             partner will be consistent and available throughout the duration of the study.&#xD;
&#xD;
          5. Based on the clinical interview, in their past, patient had experienced 'normal'&#xD;
             sexual function for at least 2 years or longer. Patient has had sexual activity at&#xD;
             least two times each month during the last 6 months and agrees to have sexual activity&#xD;
             at least two times each month for the duration of the study). Sexual activity can&#xD;
             include any activity which may result in sexual stimulation or sexual pleasure e.g.,&#xD;
             intercourse, caressing, foreplay, masturbation, and oral sex.&#xD;
&#xD;
             a. Patients who have experienced a recent major life stress (e.g., loss of income,&#xD;
             death of a family member) or relationship discord that could interfere with sexual&#xD;
             activity (except distress related to FSAD) will be excluded.&#xD;
&#xD;
          6. Women of childbearing potential must agree to continue using an acceptable form of&#xD;
             birth control during the study and agree to continue to stay on their dose of birth&#xD;
             control throughout the duration of the study. Birth control is not required for&#xD;
             confirmed same sex couples, couples with confirmed vasectomy or couples with confirmed&#xD;
             tubal ligation.&#xD;
&#xD;
               1. Acceptable forms of birth control include the following: intrauterine system&#xD;
                  [IUS], progestin and/or estrogen-containing hormonal oral contraceptives,&#xD;
                  contraceptive patch, contraceptive implant, contraceptive injection, or the&#xD;
                  copper-containing intrauterine device (IUD). Patients must be using the progestin&#xD;
                  and or estrogen-containing hormonal oral contraceptives or contraceptive patch&#xD;
                  for least 6 months prior to Visit 1 without clinically significant complications&#xD;
                  in the opinion of the Investigator. Patients must be using the IUS, IUD,&#xD;
                  contraceptive implant, or contraceptive injection for at least 3 months prior to&#xD;
                  Visit 1 without clinically significant complications in the opinion of the&#xD;
                  Investigator.&#xD;
&#xD;
               2. Vaginal forms of contraception such as contraceptive foams/gels, diaphragms,&#xD;
                  penile or vaginal condoms, contraceptive vaginal rings, and are not considered&#xD;
                  acceptable methods of birth control in this study.&#xD;
&#xD;
               3. While latex and polyisoprene condoms are not an acceptable form of contraception,&#xD;
                  they may be used for the prevention of sexually transmitted infections.&#xD;
&#xD;
          7. Patient has a body mass index (BMI) from 18 to 35 kg/m2, inclusive.&#xD;
&#xD;
          8. Patient has had a Pap smear performed within three years prior to Visit 1 and can&#xD;
             provide documentation indicating normal test results (based on current guidelines as&#xD;
             published by the U.S. Preventive Services Task Force).&#xD;
&#xD;
             a. If the patient cannot provide documentation, a Pap smear will be performed at Visit&#xD;
             1.&#xD;
&#xD;
             Patients with abnormal findings will be excluded from study participation and be&#xD;
             referred for follow-up medical care as appropriate.&#xD;
&#xD;
          9. Patient is medically healthy with no clinically significant medical history, physical&#xD;
             examination, gynecological history and examination, laboratory profiles (e.g.,&#xD;
             hematology, urinalysis), vital signs (e.g., uncontrolled hypertension), or ECGs, as&#xD;
             deemed by the Investigator.&#xD;
&#xD;
               1. Patients who have clinically significant ECG abnormalities at Visit 1 as&#xD;
                  confirmed by the Investigator will be excluded.&#xD;
&#xD;
               2. Patients with controlled, treated hypertension (&lt;140/90 mmHg) on up to two&#xD;
                  medications (excluding alpha blockers and nitrates) with a stable dose for the&#xD;
                  past 6 months will be considered eligible.&#xD;
&#xD;
               3. Patients with controlled, treated thyroid disease on a stable medication and dose&#xD;
                  for the past 6 months will be considered eligible. TSH must be within normal&#xD;
                  range (confirmed by laboratory test).&#xD;
&#xD;
         10. The participant must agree to not use vaginal hormone therapy (e.g., vaginal estrogen,&#xD;
             intravaginal prasterone), vaginal or vulvar lubricants, spermicides, creams or gels,&#xD;
             contraceptive foams or vaginal douche products throughout the study period.&#xD;
&#xD;
               1. Women who self-report abnormal physiological vaginal discharge will be excluded&#xD;
                  until abnormal physiological discharge resolves.&#xD;
&#xD;
               2. Patients using systemic (transdermal or oral) therapy must be on a stable dose&#xD;
                  for at least 6 months prior to Visit 1.&#xD;
&#xD;
         11. Patient must have a total score on the FSDS-DAO &gt;18 through visit 4.&#xD;
&#xD;
        Exclusion Criteria - For Patient Eligibility&#xD;
&#xD;
          1. Patient is nursing or pregnant (based on positive serum pregnancy test), wishes to&#xD;
             become pregnant or begin nursing during the study period or was pregnant or nursing&#xD;
             within 6 months prior to Visit 1.&#xD;
&#xD;
          2. Patient has more than one sexual partner.&#xD;
&#xD;
          3. Patient is postmenopausal (surgically induced or natural) meeting any of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Bilateral oophorectomy.&#xD;
&#xD;
               2. 12 months of spontaneous amenorrhea&#xD;
&#xD;
               3. 6 months of spontaneous amenorrhea with serum FSH levels &gt;40mIU/mL (except for&#xD;
                  those women on hormone replacement therapy)&#xD;
&#xD;
          4. Patient has any disorder or a history of any disorder that may prevent the successful&#xD;
             completion of the study in the opinion of the Investigator.&#xD;
&#xD;
          5. Patient has a significant cardiovascular, hepatic, metabolic, renal, respiratory,&#xD;
             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic,&#xD;
             genitourinary, or other unstable medical condition that would contraindicate&#xD;
             administration of study medication, interfere with study evaluation, limit study&#xD;
             participation, or confound the interpretation of study results in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          6. Patient has a history of unresolved sexual trauma or abuse that is contributing to any&#xD;
             sexual dysfunction problem (desire, arousal, orgasm, etc.) as determined by the&#xD;
             clinical interview.&#xD;
&#xD;
          7. Patient with any history of active peptic ulcers or clinically significant bleeding&#xD;
             disorders.&#xD;
&#xD;
          8. Patient with a history of clitoral priapism or conditions which may predispose them to&#xD;
             clitoral priapism (such as sickle cell anemia, multiple myeloma, or leukemia).&#xD;
&#xD;
          9. Patients with a history of myocardial infarction, stroke, or life-threatening&#xD;
             arrhythmia within 6 months prior to Visit 1; patients with resting hypotension (BP&#xD;
             &lt;90/50 mmHg); or any history of coronary disease causing angina; or congestive heart&#xD;
             failure requiring medical intervention; patients with underlying conditions which can&#xD;
             be particularly sensitive to the actions of vasodilators including patients with left&#xD;
             ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic&#xD;
             subaortic stenosis) and patients with impaired autonomic control of blood pressure, or&#xD;
             for those for which sexual activity is inadvisable due to their underlying&#xD;
             cardiovascular status.&#xD;
&#xD;
         10. Patient with a history of hearing loss (unless born completely deaf).&#xD;
&#xD;
         11. Patient has retinitis pigmentosa, even if the patient feels clinically well at the&#xD;
             time of Visit 1. Patients with retinitis pigmentosa will be identified by specifically&#xD;
             asking whether they have the condition, if there are visual signs and symptoms of the&#xD;
             condition (including questioning patients as to whether they have difficulty seeing at&#xD;
             night or in low light, and if they have any visual field deficits that indicate a loss&#xD;
             of peripheral or central vision), or if there is a family history.&#xD;
&#xD;
         12. Patient has a history of orthostatic hypotension or orthostatic hypotension which is&#xD;
             present at Visit 1, defined as a drop in systolic blood pressure ≥ 20 mm Hg, a drop in&#xD;
             diastolic blood pressure ≥ 10 mm Hg, an increase in pulse by 20 beats per minute or&#xD;
             experiencing lightheadedness or dizziness at 1 or 3 minutes after the change in&#xD;
             position from supine to standing.&#xD;
&#xD;
         13. Patient has a primary complaint of anorgasmia, vaginismus, low desire, or any other&#xD;
             primary sexual complaint aside from problems with genital arousal, as determined by&#xD;
             the clinical interview.&#xD;
&#xD;
         14. Patient has untreated dyspareunia, vulvovaginal infection or inflammation,&#xD;
             inflammatory disorders of the vulva or vagina, vestibulodynia, clitorodynia, or&#xD;
             symptomatic vulvovaginal atrophy (defined as women having ≤5% of superficial cells on&#xD;
             vaginal smear at baseline,&#xD;
&#xD;
         15. Patient has undergone major pelvic or abdominal surgery that may have caused nerve&#xD;
             damage, including, vulvectomy, colostomy, cystostomy, hysterectomy and bladder neck&#xD;
             suspension.&#xD;
&#xD;
         16. Patients with comorbid conditions that may cause underlying neurological impairment&#xD;
             (i.e., Type 1 or Type 2 diabetes, metabolic syndrome, stroke, myasthenia gravis,&#xD;
             multiple sclerosis or spinal cord damage) will be excluded.&#xD;
&#xD;
             a. Patients who are symptomatic of peripheral neuropathy will be excluded.&#xD;
&#xD;
         17. Patients with pelvic nerve damage secondary to trauma will be excluded.&#xD;
&#xD;
         18. With the exception of anxiety and depression, patient has any current and/or&#xD;
             previously reported diagnoses of DSM-IV-TR axis I disorders (e.g., schizophrenia,&#xD;
             bipolar disorder) including delirium, dementia and amnestic disorders.&#xD;
&#xD;
               1. Patients diagnosed with anxiety or depression must be controlled, as determined&#xD;
                  by the Investigator, and if on a medication (i.e., SSRIs, SNRIs, buspirone,&#xD;
                  bupropion, and benzodiazepines), on a stable dose for at least the past 6 months.&#xD;
&#xD;
               2. Patients must have a total score &lt;10 indicating mild depression on the Patient&#xD;
                  Health Questionnaire-8 (PHQ-8, Appendix G) (a screening and assessment instrument&#xD;
                  for depression).&#xD;
&#xD;
               3. Patients must have a total score &lt;6 indicating mild anxiety on the Generalized&#xD;
                  Anxiety Disorder (GAD-7, Appendix H) (a screening and assessment instrument for&#xD;
                  anxiety).&#xD;
&#xD;
               4. Patients who have any history of anti-psychotic therapy within the last year will&#xD;
                  be excluded.&#xD;
&#xD;
         19. Patients that have a history of gynecological cancer or are under active treatment (or&#xD;
             recently completed treatment within the last 6 months) for any cancer which in the&#xD;
             Investigator's judgement would interfere with the patient's ability to successfully&#xD;
             complete the study will be excluded.&#xD;
&#xD;
               1. Patients who have been previously treated for dysplasia (precancerous changes)&#xD;
                  may be included as long as the patient received localized treatment (e.g.,&#xD;
                  cryosurgery or laser).&#xD;
&#xD;
               2. Patients with a history of radiation to the pelvis will be excluded.&#xD;
&#xD;
         20. Patient has any surgical or medical condition that may interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the test article in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
         21. Patient self-reports a history of substance abuse within two years prior to Visit 1 or&#xD;
             exhibits signs of current substance abuse based on Investigator judgement.&#xD;
&#xD;
         22. Patient self-reports a history of alcohol abuse in the two years prior to Visit 1 or&#xD;
             exhibits signs of current alcohol abuse based on Investigator judgement.&#xD;
&#xD;
         23. Patient has a history of non-arteritic ischemic optic neuropathy (NAION) or any&#xD;
             underlying NAION risk factors.&#xD;
&#xD;
         24. Patient whose sexual function was affected (enhanced or worsened) by any medication&#xD;
             within 28 days before Visit 1 and at any time prior to the No Drug Run-in Period of&#xD;
             the study.&#xD;
&#xD;
         25. Patient is currently receiving treatment or has received treatment within 1 month (28&#xD;
             days) prior to Visit 1 of any of the following medications: guanylate cyclase&#xD;
             stimulators (e.g., Riociguat), clonidine, strong CYP3A4 inhibitors, nitric oxide&#xD;
             donors, such as organic nitrates or organic nitrites, and alpha blockers.&#xD;
&#xD;
             a. Patients who are currently receiving treatment or have received treatment in the&#xD;
             past 3 months for FSAD symptoms, pharmacologic (e.g., PDE5 inhibitors in any form&#xD;
             except Sildenafil Cream, 3.6% or other experimental therapies used to enhance the&#xD;
             arousal response) or non-pharmacologic treatment (e.g., sex therapy), will also be&#xD;
             excluded.&#xD;
&#xD;
         26. Patient has positive findings from the urine drug screen (e.g., amphetamines,&#xD;
             barbiturates, cocaine, methadone, and opiates). Patients who test positive for&#xD;
             amphetamines but are being treated for ADHD with a confirmed legal prescription will&#xD;
             be allowed to participate.&#xD;
&#xD;
         27. Patient has positive findings for sexually transmitted infection (gonorrhea,&#xD;
             trichomoniasis, chlamydia), and human immunodeficiency virus (HIV) antibodies.&#xD;
&#xD;
         28. Patient reports having an outbreak (blisters, warts, or vesicles) due to any of the&#xD;
             following sexually transmitted diseases: genital herpes or HPV at any time point in&#xD;
             the past three months.&#xD;
&#xD;
         29. Patient has participated in any clinical research study evaluating another&#xD;
             investigational drug or therapy within 30 days before Visit 1 (or 6 half-lives of the&#xD;
             investigational agent, whichever is longer) and agrees not to participate in another&#xD;
             clinical research study throughout the duration of the study.&#xD;
&#xD;
         30. Patient has any clinically significant abnormal findings on vulvar-vaginal examination&#xD;
             performed during the physical and gynecological exams at Visit 1 (e.g., genital skin&#xD;
             breaks, irritation, dermatoses, or lesions).&#xD;
&#xD;
         31. Patient currently has moderate to severe current vaginitis, a vaginal infection&#xD;
             including bacterial vaginosis, a yeast infection or the presence of yeast based on the&#xD;
             Nucleic Acid Amplification (NAAT).&#xD;
&#xD;
               1. If the patient has a vaginal infection or a positive test for yeast during the&#xD;
                  screening visit, they may be treated, and the screening visit rescheduled.&#xD;
&#xD;
               2. If the patient develops a vaginal infection following enrollment into the study,&#xD;
                  study drug will be withheld, and the patient will be treated for the infection.&#xD;
                  If the infection cannot be resolved within two weeks the patient will be&#xD;
                  withdrawn from the study. Treatment of vaginal infections will be allowed twice&#xD;
                  following enrollment. If the patient develops a third vaginal infection they will&#xD;
                  be withdrawn from the study.&#xD;
&#xD;
         32. Patient has a pelvic or urinary tract infection.&#xD;
&#xD;
               1. If the patient has a urinary tract infection during the screening visit, they may&#xD;
                  be treated, and the screening visit rescheduled.&#xD;
&#xD;
               2. If the patient develops a urinary tract infection following enrollment into the&#xD;
                  study, study drug will be withheld, and the patient will be treated for the&#xD;
                  infection. If the infection cannot be resolved within two weeks the patient will&#xD;
                  be withdrawn from the study. Treatment of urinary tract infections will be&#xD;
                  allowed twice following enrollment. If the patient develops a third urinary tract&#xD;
                  infection they will be withdrawn from the study.&#xD;
&#xD;
         33. Patient self-reports a known hypersensitivity or adverse reaction to any ingredients&#xD;
             in the Investigational Product (IP).&#xD;
&#xD;
         34. The patient is an immediate family member, a study site employee, or is in a dependent&#xD;
             relationship with a study site employee or anyone who is involved in the conduct of&#xD;
             the study (e.g., spouse, parent, child, sibling) or may consent under duress.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathy Cornell</last_name>
    <phone>774-473-4414</phone>
    <email>kcornell@strategicscience.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Trials-Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research -Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Healthcare</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Connecticut Research, LLC</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intimmedicine Specialists</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMR Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions-Orlando</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Age Medical Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research - Pasco County</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Healthcare Clinical Data, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AGILE Clinical Research Trials</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosemark Women Care Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Institute for Women's Sexual Health</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praetorian Pharmaceutical Research</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's OB-GYN, P.C. dba Saginaw Valley Medical</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omaha OB GYN Associates, P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Essential Women's Health Associates</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Office of Doctor Rex G. Mabey Junior</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>086489</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology - Bloomfield</name>
      <address>
        <city>Millburn</city>
        <state>New Jersey</state>
        <zip>07041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Specialized Women's Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suffolk Obstetrics and Gynecology</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Cleveland (Rapid Medical Research)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research, inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Landerbrook</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rivus Wellness &amp; Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Providence</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions - Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Associates - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TMC Life Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maximos Obstetrics and Gynecology</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc.</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tidewater Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Women's Health Research - Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sexual Disorder</keyword>
  <keyword>Arousal Disorder</keyword>
  <keyword>FSAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunction, Physiological</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

